Table 1. Characteristics of patient... | American Society of Hematology

Table 1.

Characteristics of patient samples

Patient no.	Sex	Age, y	FAB subtype	WBCs, × 10⁹/L	Blasts, %	Cytogenetics	FLT-3 ITD
51	M	26	AML2	6.6	88	46XY	ND
62	F	48	AML0	2.4	85	91XXXX,-17	–
19	F	67	AML2	200	72	46XX	–
27	M	66	AML2	26	66	t(8,21)	–
18	M	25	AML4	150	74	46XY	ND
24	M	44	AML4Eo	42	73	inv(16)	–
29	M	59	AML5	4.4	83	46XY	–
89	M	52	AML2	120	90	46XY	–
102	M	55	AML4	63	92	46XY	+
110	M	36	AML4	50	95	46XY	–

Patient no.	Sex	Age, y	FAB subtype	WBCs, × 10⁹/L	Blasts, %	Cytogenetics	FLT-3 ITD
51	M	26	AML2	6.6	88	46XY	ND
62	F	48	AML0	2.4	85	91XXXX,-17	–
19	F	67	AML2	200	72	46XX	–
27	M	66	AML2	26	66	t(8,21)	–
18	M	25	AML4	150	74	46XY	ND
24	M	44	AML4Eo	42	73	inv(16)	–
29	M	59	AML5	4.4	83	46XY	–
89	M	52	AML2	120	90	46XY	–
102	M	55	AML4	63	92	46XY	+
110	M	36	AML4	50	95	46XY	–

All patients listed showed constitutive PI3K activation as defined by Akt phosphorylation on Ser473 after starvation in serum-free medium for 4 hours. Blast percentages were determined based on differential of bone marrow aspirations prior to Ficoll sedimentation. WBCs indicates white blood cells; ITD, internal tandem duplication; ND, not done. None of the samples listed was positive for D835 mutation in FLT-3 (data not shown).

View Large

This Feature Is Available To Subscribers Only